Statin treatment patterns and clinical profile of patients with risk factors for coronary heart disease defined by National Cholesterol Education Program Adult Treatment Panel III

Abstract

Objective:

To compare clinical characteristics, statin treatment patterns and adherence among patients at different risk for coronary heart disease (CHD) as defined by National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guidelines.

Methods:

Patients ≥18 years old with ≥1 claim for dyslipidemia, ≥1 statin claim, or ≥1 LDL-C value ≥100 mg/dL were identified from 1 January 2007 to 31 July 2012. Patients were classified as low risk (LR) (0–1 risk factor: hypertension, age ≥45 years [men] or ≥55 years [women], or low HDL-C), moderate/moderately high risk (MR) (≥2 risk factors), high risk (HR) (CHD or CHD risk equivalent), or very high risk (VHR) (acute coronary syndrome, or established cardiovascular disease plus diabetes or metabolic syndrome). Medication use and lipid levels during the 12 months before and statin use during the 6 months after index were compared across risk groups.

Results:

There were 1,524,351 LR, 242,357 MR, 188,222 HR, and 57,469 VHR patients identified. Statin use was observed in 15% of all patients, but was higher in the VHR group (45%) versus LR (12%), MR (18%), and HR (29%) groups. Simvastatin accounted for 50%–52% of all statin use, and average statin dose was higher among VHR patients compared with all other groups. Adherence was low overall (mean proportion of days covered [PDC]: 0.57), but higher among VHR (0.69) versus others (mean PDC: 0.55, 0.59, and 0.59 in LR, MR, and HR groups, respectively).

Conclusions:

Statin treatment was low across all risk groups, and VHR patients had higher doses and better adherence compared with other risk groups. However, adherence was not optimal, indicating a potential limited benefit from statin treatment.

Keywords::

• Adherence
• Coronary heart disease
• Dyslipidemia
• Retrospective
• Statins

Transparency

Declaration of funding

AstraZeneca funded this research.

Declaration of financial/other relationships

D.A. has disclosed that she is an employee of AstraZeneca. S.B. has disclosed that he was an employee of AstraZeneca at the time this study was conducted. D.M.K. and O.T. are employees of HealthCore Inc. which received funding from AstraZeneca to conduct the research.

CMRO peer reviewers on this manuscript have received an honorarium from CMRO for their review work, but have no relevant financial or other relationships to disclose.

Acknowledgments

Diana Frame provided writing and other editorial support for this manuscript.